These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 28544684)
21. [New methods in insulin treatment]. Neuwirth G Orv Hetil; 2005 Jan; 146(3):111-6. PubMed ID: 15693442 [TBL] [Abstract][Full Text] [Related]
22. Prevailing therapeutic regimes and predictive factors for prandial insulin substitution in 26 687 children and adolescents with Type 1 diabetes in Germany and Austria. Knerr I; Hofer SE; Holterhus PM; Näke A; Rosenbauer J; Weitzel D; Wolf J; Holl RW Diabet Med; 2007 Dec; 24(12):1478-81. PubMed ID: 17971184 [TBL] [Abstract][Full Text] [Related]
23. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM. Kanc K; Janssen MM; Keulen ET; Jacobs MA; Popp-Snijders C; Snoek FJ; Heine RJ Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173 [TBL] [Abstract][Full Text] [Related]
24. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial. Nimri R; Danne T; Kordonouri O; Atlas E; Bratina N; Biester T; Avbelj M; Miller S; Muller I; Phillip M; Battelino T Pediatr Diabetes; 2013 May; 14(3):159-67. PubMed ID: 23448393 [TBL] [Abstract][Full Text] [Related]
25. [The diabetic child and the specifics of insulin therapy]. Dirlewanger M; Perrenoud L; Castellsague-Perolini M; Schwitzgebel VM Rev Med Suisse; 2007 Apr; 3(107):994-1000. PubMed ID: 17526373 [TBL] [Abstract][Full Text] [Related]
26. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c: response to Retnakaran et al. Blumer I Diabetes Care; 2005 Mar; 28(3):763; author reply 763-4. PubMed ID: 15735237 [No Abstract] [Full Text] [Related]
27. 20 Years of Pediatric Benchmarking in Germany and Austria: Age-Dependent Analysis of Longitudinal Follow-Up in 63,967 Children and Adolescents with Type 1 Diabetes. Bohn B; Karges B; Vogel C; Otto KP; Marg W; Hofer SE; Fröhlich-Reiterer E; Holder M; Plamper M; Wabitsch M; Kerner W; Holl RW; PLoS One; 2016; 11(8):e0160971. PubMed ID: 27532627 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Danne T; Becker RH; Heise T; Bittner C; Frick AD; Rave K Diabetes Care; 2005 Sep; 28(9):2100-5. PubMed ID: 16123473 [TBL] [Abstract][Full Text] [Related]
30. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Garg SK; Ellis SL; Ulrich H Expert Opin Pharmacother; 2005 Apr; 6(4):643-51. PubMed ID: 15934890 [TBL] [Abstract][Full Text] [Related]
31. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Becker RH; Frick AD; Nosek L; Heinemann L; Rave K Diabetes Care; 2007 Oct; 30(10):2506-7. PubMed ID: 17675541 [No Abstract] [Full Text] [Related]
32. Limitations to subcutaneous insulin administration in type 1 diabetes. Chen JW; Christiansen JS; Lauritzen T Diabetes Obes Metab; 2003 Jul; 5(4):223-33. PubMed ID: 12795655 [No Abstract] [Full Text] [Related]
33. Age-specific advantages of continuous subcutaneous insulin infusion as compared with multiple daily injections in pediatric patients: one-year follow-up comparison by matched-pair analysis. Kordonouri O; Hartmann R; Lauterborn R; Barnekow C; Hoeffe J; Deiss D Diabetes Care; 2006 Jan; 29(1):133-4. PubMed ID: 16373909 [No Abstract] [Full Text] [Related]
34. Lipoatrophy in children, adolescents and adults with insulin pump treatment: Is there a beneficial effect of insulin glulisine? Kordonouri O; Biester T; Weidemann J; Ott H; Remus K; Grothaus J; Pisarek N; Hartmann R; Adolph K; Lange K; Danne T Pediatr Diabetes; 2020 Nov; 21(7):1285-1291. PubMed ID: 32738019 [TBL] [Abstract][Full Text] [Related]
35. Subcutaneous insulin administration in infants and toddlers. Dhingra M; Priya G; Dhingra A; Kalra S J Pak Med Assoc; 2018 Dec; 68(12):1840-1842. PubMed ID: 30504953 [TBL] [Abstract][Full Text] [Related]
36. Letter written in response to van bon et Al.: "Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial". Jovanovič L Diabetes Technol Ther; 2011 Aug; 13(8):869-70; author response 871. PubMed ID: 21732826 [No Abstract] [Full Text] [Related]
37. Diabetes Technology and Therapy in the Pediatric Age Group. Maahs DM; Shalitin S Diabetes Technol Ther; 2018 Feb; 20(S1):S114-S127. PubMed ID: 29437470 [No Abstract] [Full Text] [Related]
38. Overnight versus 24 hours of continuous subcutaneous insulin infusion as supplement to oral antidiabetic drugs in type 2 diabetes. Parkner T; Laursen T; Chen JW; Møller MK; Thomsen HF; Jørgensen C; Smedegaard JS; Lauritzen T; Christiansen JS J Diabetes Sci Technol; 2007 Sep; 1(5):704-10. PubMed ID: 19885138 [TBL] [Abstract][Full Text] [Related]
39. Assessment of distance from skin surface to muscle for evaluation of the risk of inadvertent intramuscular insulin injection at potential injection sites among patients attending a tertiary care children's hospital in Sri Lanka-an observational study. Kodikara SKYI; Kalubowila J; Atapattu N; Warapitiya DS; Wijayabandara MDMS; Jayasekara LMDT; Arunthavanathan A; Kempitiya BCTANWMRCS; de Silva KSH; de Abrew K Arch Pediatr; 2020 Jul; 27(5):244-249. PubMed ID: 32461034 [TBL] [Abstract][Full Text] [Related]
40. Progress in the treatment of childhood diabetes mellitus and obesity. Wilson DM J Pediatr Endocrinol Metab; 2002 May; 15 Suppl 2():745-9. PubMed ID: 12092689 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]